BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-264@pharmaconomics
DTSTAMP:20260707T003843Z
DTSTART;VALUE=DATE:20260928
DTEND;VALUE=DATE:20260929
SUMMARY:BFRI PDUFA — Ameluz
DESCRIPTION:The FDA's approval decision on Ameluz for superficial basal cell carcinoma (sBCC) is due Sep 28\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1858685/000149315226011545/ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/264
URL:https://www.pharmaconomics.com/e/264
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BFRI catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR